A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
A Phase I/IIa, Single Site, Open-Label, Ascending Dose Study to Evaluate the Safety and Efficacy of OPF-310 [Encapsulated Porcine Islet Cells for Xenotransplantation] in Subjects With Type 1 Diabetes Mellitus
Sponsor: Otsuka Pharmaceutical Factory, Inc.
Listed as NCT06575426, this PHASE1/PHASE2 trial focuses on Autoimmune Diseases and Diabetes Mellitus, Type 1 and remains actively recruiting participants. Sponsored by Otsuka Pharmaceutical Factory, Inc., it has been updated 8 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2025 — Feb 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
▶ Show 3 earlier versions
-
May 2025 — Jul 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE1/PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Apr 2025 [monthly]
Not Yet Recruiting PHASE1/PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Otsuka Pharmaceutical Factory, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .